# ZUMA-3 (NCT02614066)

> A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02614066
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Kite, A Gilead Company
- Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Interventions: brexucabtagene autoleucel; Cyclophosphamide; Fludarabine
- Enrollment: 125
- Primary outcome: Phase 1: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
- Primary outcome: Phase 2: Overall Complete Remission (OCR) Rate (Complete Remission [CR]+ Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed Per Independent Review

## Commentary we found

- YouTube: 12
- X threads: 8
- Podcasts: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=zuma-3-nct02614066

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02614066", "email": "<work email>"}; the inbox owner confirms by the emailed link.